Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer

Niranjan J Sathianathen, Philipp Dahm, Sarah Jane Brown, Makinna Oestreich, Shilpa Gupta, Badrinath R Konety, Frank Kunath

Research output: Contribution to journalArticlepeer-review

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effects of early abiraterone acetate in combination with androgen deprivation therapy for newly diagnosed metastatic hormone-sensitive prostate cancer.

Original languageEnglish (US)
Article numberCD013245
JournalCochrane Database of Systematic Reviews
Volume2019
Issue number1
DOIs
StatePublished - Jan 24 2019

Bibliographical note

Publisher Copyright:
© 2019 The Cochrane Collaboration.

Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.

Fingerprint Dive into the research topics of 'Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer'. Together they form a unique fingerprint.

Cite this